Skip to Content
Merck
  • A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk.

A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk.

Journal of applied toxicology : JAT (2016-08-03)
Takafumi Tomida, Hayao Okamura, Tsuyoshi Yokoi, Yoshihiro Konno
ABSTRACT

The approach for predicting the degree of drug-induced liver injury (DILI) risk was investigated quantitatively in a modified multiparametric assay using HepaRG cells. Thirty-eight drugs were classified by DILI risk into five categories based on drug labels approved by the Food and Drug Administration (FDA) as follows: withdrawn (WDN), boxed warning (BW), warnings and precautions (WP), adverse reactions (AR), and no match (NM). Also, WP was classified into two categories: high and low concern. Differentiated HepaRG cells were treated with drugs for 24 h. The maximum concentration was set at 100-fold the therapeutic maximum plasma concentration (C

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Troglitazone, ≥98% (HPLC)
Sigma-Aldrich
Rosiglitazone, ≥98% (HPLC)
Sigma-Aldrich
Differentiated HepaRG Cells Cryopreserved
Sigma-Aldrich
Dasatinib
Sigma-Aldrich
Imatinib
Sigma-Aldrich
Lapatinib
Sigma-Aldrich
HepaRG Thawing and Plating Medium Supplement
Sigma-Aldrich
HepaRG Maintenance and Metabolism Medium Supplement
Sigma-Aldrich
HepaRG Induction Medium Supplement
Sigma-Aldrich
HepaRG Serum Free Induction Medium Supplement
Sigma-Aldrich
HepaRG Serum Free Induction Medium Supplement with Antibiotics
Sigma-Aldrich
Zafirlukast, ≥98% (HPLC)
Supelco
Posaconazole, VETRANAL®, analytical standard
Sigma-Aldrich
HepaRG Thawing and Plating Medium Supplement with Antibiotics
Sigma-Aldrich
HepaRG Maintenance and Metabolism Medium Supplement with Antibiotics
Sigma-Aldrich
HepaRG Induction Medium Supplement with Antibiotics
Sigma-Aldrich
Nilotinib
Sigma-Aldrich
Pioglitazone